ClinicalTrials.gov
public full text
Public Domain
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
This is a single-institution, phase II study to determine the event-free survival at 1 year post allogeneic transplant and serial mesenchymal stem cell (MSC) infusions from a related donor (HLA identical, mismatched or haploidentical) or matched unrelated donor for the biochemical correction of severe epidermolysis bullosa (EB).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Umbilical Cord Derived Mesenchymal Stem Cells Transplantation for Active and Refractory Systemic Lupus Erythematosus#1364094
- Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion#1111569
- CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies#184848
- Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention#1101964
- Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platform#359889
Record · ID 1230639
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive